Prosensa Announces Shareholder Approval of Certain Matters

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Prosensa Announces Shareholder Approval of Certain Matters Relating to the BioMarin Tender Offer

Leiden, The Netherlands, Jan. 13, 2015 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that during an extraordinary general meeting of shareholders held today, Prosensa obtained shareholder approval for certain matters relating to the previously disclosed tender offer by BioMarin to purchase all of the outstanding shares of Prosensa. 

This approval includes approval of certain transactions that are intended to be consummated after the completion of the tender offer.  Obtaining shareholders' approval of the items submitted to a vote at the meeting satisfies a condition to the closing of the tender offer.  The approvals will become effective upon the closing. 

On December 12, 2014, BioMarin Falcons B.V. and BioMarin Giants B.V., each a wholly owned direct or indirect subsidiary of BioMarin Pharmaceutical Inc., commenced the tender offer to acquire all of the outstanding ordinary shares of Prosensa for $17.75 per share upfront plus a right to receive up to an additional $4.14 per share based on regulatory approval of drisapersen in the United States and Europe, in each case, without interest and less any applicable withholding taxes.   The tender offer is set to expire at 6:00 p.m., New York City time, on January 14, 2015, unless extended or earlier terminated.  The tender offer remains subject to certain conditions described in the tender offer statement on Schedule TO filed by BioMarin Falcons B.V. and BioMarin Giants B.V. with the United States Securities and Exchange Commission (the "SEC") on December 12, 2014 and amended on December 24, 2014, December 31, 2014 and January 6, 2015, including the condition that at least 80% of Prosensa's outstanding shares be validly tendered and not withdrawn prior to the expiration of the offer.

Notes to editors

About Prosensa Holding N.V.

Prosensa  is a biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), Myotonic Dystrophy and Huntington's disease.

Prosensa's current portfolio includes six compounds for the treatment of DMD, all of which have received orphan drug status in the United States and the European Union. The compounds use an innovative technique called exon-skipping to provide a personalized medicine approach to treat different populations of DMD patients. www.prosensa.com

About DMD

Duchenne muscular dystrophy is the most common fatal genetic disorder diagnosed in childhood, affecting approximately up to 1 in 3,500 live male births. DMD is caused by mutations in the gene that encodes for dystrophin, a protein that is important for muscle function. Patients suffer from progressive loss of muscle function, often making them wheelchair bound before the age of 12. Respiratory and cardiac muscle can also be affected by the disease. Few patients survive the age of 30. There is currently no cure for DMD.

Forward Looking Statements

SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING THE EXPECTED CONSUMMATION OF THE ACQUISITION, WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, INCLUDING THE SATISFACTION OF CLOSING CONDITIONS FOR THE ACQUISITION, SUCH AS REGULATORY APPROVAL FOR THE TRANSACTION AND THE TENDER OF AT LEAST 80% OF THE OUTSTANDING ORDINARY SHARES OF PROSENSA, THE POSSIBILITY THAT THE TRANSACTION WILL NOT BE COMPLETED AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN PROSENSA'S PUBLIC FILINGS WITH THE SEC, INCLUDING THE "RISK FACTORS" SECTIONS OF PROSENSA'S ANNUAL REPORT ON FORM 20-F FOR THE YEAR ENDED DECEMBER 31, 2013, AS WELL AS THE TENDER OFFER DOCUMENTS FILED BY BIOMARIN AND THE SOLICITATION/RECOMMENDATION STATEMENT FILED BY PROSENSA.  THESE STATEMENTS ARE BASED ON CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS, AND INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS TO BE MATERIALLY DIFFERENT FROM ANY FUTURE STATEMENTS.  THESE STATEMENTS ARE GENERALLY IDENTIFIED BY WORDS OR PHRASES SUCH AS "BELIEVE", "ANTICIPATE", "EXPECT", "INTEND", "PLAN", "WILL", "MAY", "SHOULD", "ESTIMATE", "PREDICT", "POTENTIAL", "CONTINUE" OR THE NEGATIVE OF SUCH TERMS OR OTHER SIMILAR EXPRESSIONS.  IF UNDERLYING ASSUMPTIONS PROVE INACCURATE OR UNKNOWN RISKS OR UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS AND THE TIMING OF EVENTS MAY DIFFER MATERIALLY FROM THE RESULTS AND/OR TIMING DISCUSSED IN THE FORWARD-LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE STATEMENTS.  BIOMARIN AND PROSENSA DISCLAIM ANY INTENT OR OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF DEVELOPMENTS OCCURRING AFTER THE PERIOD COVERED BY THIS REPORT OR OTHERWISE.

Additional Information and Where to Find it

THIS COMMUNICATION IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE EITHER AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL ANY ORDINARY SHARES OF PROSENSA OR ANY OTHER SECURITIES.

BIOMARIN HAS FILED A TENDER OFFER STATEMENT ON SCHEDULE TO, INCLUDING AN OFFER TO PURCHASE, A LETTER OF TRANSMITTAL AND RELATED MATERIALS, WITH THE SEC, AND PROSENSA HAS FILED A SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WITH THE SEC. THE OFFER TO PURCHASE PROSENSA SHARES IS ONLY BEING MADE PURSUANT TO THE OFFER TO PURCHASE, THE LETTER OF TRANSMITTAL AND RELATED MATERIALS FILED WITH THE SEC BY BIOMARIN AS A PART OF ITS SCHEDULE TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE OFFER, INCLUDING ITS TERMS AND CONDITIONS, AND SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE OFFER. INVESTORS AND SECURITY HOLDERS MAY OBTAIN FREE COPIES OF THESE STATEMENTS AND OTHER MATERIALS FILED WITH THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV , OR BY DIRECTING REQUESTS FOR THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 TO PROSENSA'S INVESTOR RELATIONS DEPARTMENT, J.H. OORTWEG 21, 2333 CH LEIDEN, THE NETHERLANDS, TELEPHONE NUMBER +31 (0)71 33 22 100, OR FROM PROSENSA'S WEBSITE, IR.PROSENSA.EU, OR, FOR THE OFFER TO PURCHASE ON SCHEDULE TO AND THE OTHER RELATED MATERIALS (A PORTION OF WHICH ARE ATTACHED HERETO AS APPENDIX C), TO THE INFORMATION AGENT FOR THE TENDER OFFER, MORROW & CO., TOLL-FREE AT (800)-267-0201 OR VIA EMAIL AT PROSENSA.INFO@MORROWCO.COM.

Prosensa Holding N.V. Celia Economides, Senior Director IR & Corporate Communications Phone: +1 917 941 9059 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 6

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 138

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 41

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 179

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 61

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 153

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 114

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 192

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 56

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 200

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading

Top 5 Most Recently Viewed Articles

Edward H. McKay Takes Helm as New CEO of Shenandoah Telecommunications

Updated Category News Views 218

Leadership Change at Shenandoah Telecommunications Shenandoah Telecommunications Company, often referred to as "Shentel," has officially announced a significant leadership transition. Edward H. "Ed" McKay has been appointed as the new President and Chief Executive Officer. This change is set to take place on a specified date in the near future, as current President and...

Continue Reading
Projected Growth of Security Printing Market to USD 5.79 Billion

Updated Category News Views 118

Security Printing Market Overview SkyQuest has forecasted that the global security printing market will achieve a remarkable valuation of USD 5.79 billion by the year 2031. This represents a compound annual growth rate (CAGR) of 3.10% during the projection period, which spans from 2024 to 2031. The driving force behind this growth is the collective efforts of governments...

Continue Reading
Prosperity Bancshares, Inc. and Southwest Bancshares Unite

Updated Category News Views 136

Prosperity Bancshares, Inc. Merges with Southwest Bancshares In an exciting development for the banking sector, Prosperity Bancshares, Inc. has officially completed its merger with Southwest Bancshares, Inc. This strategic consolidation promises to bring enhanced customer service and a richer array of financial products, benefiting customers in various ways. As the...

Continue Reading
Revolutionizing AI Security Standards: Wallarm's A2AS Framework

Updated Category News Views 970

Wallarm's Role in Advancing AI Security Today, Wallarm announced its significant contribution to the release of "A2AS: Agentic AI Runtime Security and Self-Defense." This innovative project, spearheaded by Eugene Neelou, aligns various industry leaders, including AWS, Cisco, Google, and more, to fortify the foundation of AI security protocols. The A2AS Framework: A New...

Continue Reading
R2 Wireless Expands Operations with New US Leadership Team

Updated Category News Views 355

R2 Wireless Expands Operations with New Leadership R2 has made a significant stride in addressing the increasing threats and advancements in Electronic Warfare and Counter-UAS programs. The company has launched its US operations and appointed Mr. Cordell Bennigson as its US CEO. Strategic Move for Growth This strategic decision comes in response to the rising global...

Continue Reading